
Merck & Pfizer’s bladder cancer drug gets NICE approval
The National Institute for Health and Care Excellence (NICE) has overturned a previous decision where it chose not to recommend the immunotherapy BAVENCIO (avelumab) for the treatment of bladder cancer. The decision comes after avelumab’s developers, Merck KGaA and Pfizer, appealed the prior Final… Read More
